Recent studies suggest that its inhibition could lead to a milder phenotype of myelin oligodendrocyte glycoprotein (MOG)-induced EAE, suggesting that like DOCK8 it could be a target for treatment of MS (120). This evidence concerns the gene MOG and myeloid sarcoma.